Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
NEW YORK, Sept. 5, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the following upcoming healthcare investor conferences:
STIFEL NICOLAUS 2012 HEALTHCARE CONFERENCE
- Presentation Date: Thursday, September 6, 2012
- Presentation Time: 1:30pm ET
RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE
- Presentation Date: Monday, September 10, 2012
- Presentation Time: 3:40pm ET
2012 UBS GLOBAL LIFE SCIENCES CONFERENCE
- Presentation Date: Thursday, September 20, 2012
- Presentation Time: 11:00am ET
Each of these presentations will be live audio webcast and accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
SOURCE Keryx Biopharmaceuticals, Inc.
More by this Source
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
May 07, 2013, 16:30 ET
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Mar 14, 2013, 08:56 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.